IVF center
Alexandria, Egypt
NCT Number: NCT05197374
Depended on the hypothesis that growth asynchrony of antral follicles is a consequence of the gradual follicle stimulating hormone (FSH) elevation that occurs during the late luteal phase, the aim of this work is to study the effect of estradiol pretreatment on follicular synchronization and intracytoplasmic sperm injection (ICSI) outcome in antagonist cycles
Looking for future studies?
Notify Me20 year–37 year
Female
Interventional
Phase 4
Alexandria, Egypt
Gonadotropin-releasing hormone antagonist (GnRH-ant) cycles are characterized by higher patient acceptability with more attention being directed to the potential effect of steroid pretreatment to program antagonist protocol cycles, as marked size discrepancies of growing follicles reflect incoordinated maturation of follicular-oocyte complexes and complicates clinical criteria for human chorionic gonadotropin (hCG) administration. This phenomenon is associated with fewer mature oocytes and resulting embryos, which limits sufficient embryo selection for embryo transfer. Indeed, the large number of available embryos represented an important prognostic factor of invitro-fertilization (IVF) outcome, particularly in poor prognosis patients, possibly by increasing the probability that at least one good-quality embryo will be selected for embryo transfer. During COH, a better understanding of follicular development has resulted in the improvement of strategies for ovarian stimulation. This approach represents a potential and more physiological alternative to GnRH agonist or oral contraceptive pills pre-treatment in a trial to synchronize multi-follicular development and improve controlled ovarian hyperstimulation (COH) results. The present study is a randomized controlled trial that investigated whether E2 pre-treatment during the luteal phase affects developmental characteristics of growing follicles during COH. It depended on the hypothesis that growth asynchrony of antral follicles is a consequence of the gradual FSH elevation that occurs during the late luteal phase, thus testing for detection of the effect of luteal estradiol on follicular synchronization and its effect on ICSI outcome.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Estradiol valerate 2 mg (two tablet once daily) started 5 days before expected menses (or 7 days after ovulation of previous cycle). After start of menses, estradiol pretreatment was stopped and controlled ovarian stimulation started.
Other names: Progynova
Time frame: 7-16 days after start of controlled ovarian stimulation.
number of days from the start of controlled ovarian stimulation on day 2 of menses until the day of hCG administration until day of hCG administration
Time frame: 7-16 days after start of controlled ovarian stimulation.
number of gonadotropin ampules used from the start of controlled ovarian stimulation on day 2 of menses until the day of hCG administration
Time frame: 7-16 days after start of controlled ovarian stimulation.
number of follicles by ultrasound scan on day of hCG administration
Time frame: 7-16 days after start of controlled ovarian stimulation.
serum level of estradiol pg/dl and progesterone ng/dl on day of hCG administration
Time frame: 7-16 days after start of controlled ovarian stimulation.
thickness of endometrium in mm on day of hCG
Time frame: 36 hours after oocyte retrieval.
number of metaphase II oocytes after denudation
Time frame: 3 days after oocyte retrieval.
number of grade 1 and grade 2 day 3 embryos
Time frame: 14 days after embryo transfer
the number of positive pregnancies (defined as serum B-hCG more than 5 miu/ml measured 14 days after embryo transfer) divided by the number of embryo transfer procedures.
Time frame: 2 weeks after positive pregnancy test
The number of clinical pregnancies (defined as the presence of a gestational sac with positive heart beat detected by transvaginal ultrasound scan 2 weeks after positive pregnancy test) divided by the number of embryo transfer procedures
Alexandria University
Other
Studying The Effect of Estradiol Pretreatment on Follicular Synchronization and Intracytoplasmic Sperm Injection (ICSI) Outcome in Antagonist Cycles
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02108665
Female Infertility, Female Urogenital Diseases
Nice, France
View Trial DetailsNCT07398924
Anovulatory Infertility, Female Infertility
Van, Di̇yarbakir, Turkey (Türkiye)
View Trial DetailsNCT06684951
Female Infertility, Female Urogenital Diseases
Baghdad, Iraq
View Trial DetailsNCT03737253
Female Infertility, Female Urogenital Diseases
Poznan, Poland
View Trial Details